Your browser doesn't support javascript.
loading
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
Turecek, Peter L; Peck, Rachel C; Rangarajan, Savita; Reilly-Stitt, Christopher; Laffan, Michael A; Kazmi, Rashid; James, Izabela; Dushianthan, Ahilanandan; Schrenk, Gerald; Gritsch, Herbert; Ewenstein, Bruce M; Mellgard, Bjorn; Erdlenbruch, Wolfhard; Jain, Nisha; Binder, Nikolaus B; Mumford, Andrew D.
Afiliación
  • Turecek PL; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria.
  • Peck RC; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Rangarajan S; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; K J Somaiya Superspecialty Hospital and Research Centre, Mumbai, India.
  • Reilly-Stitt C; University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
  • Laffan MA; Imperial College London, Hammersmith Hospital, London, United Kingdom.
  • Kazmi R; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • James I; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Dushianthan A; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Schrenk G; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria.
  • Gritsch H; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria.
  • Ewenstein BM; Baxalta US Inc., a Takeda company, Cambridge, MA, USA.
  • Mellgard B; Baxalta US Inc., a Takeda company, Cambridge, MA, USA.
  • Erdlenbruch W; Baxalta GmbH, a Takeda company, Zurich, Switzerland.
  • Jain N; Baxalta US Inc., a Takeda company, Cambridge, MA, USA.
  • Binder NB; Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Vienna, Austria.
  • Mumford AD; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. Electronic address: a.mumford@bristol.ac.uk.
Thromb Res ; 201: 100-112, 2021 05.
Article en En | MEDLINE | ID: mdl-33662796
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / Proteínas Recombinantes / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Thromb Res Año: 2021 Tipo del documento: Article País de afiliación: Austria
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / Proteínas Recombinantes / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Thromb Res Año: 2021 Tipo del documento: Article País de afiliación: Austria